Skip to main content
Top
Published in: Current Diabetes Reports 10/2019

Open Access 01-10-2019 | Obesity | Obesity (KM Gadde, Section Editor)

Medical Devices in Obesity Treatment

Authors: Aruchuna Ruban, Akash Doshi, Erika Lam, Julian P. Teare

Published in: Current Diabetes Reports | Issue 10/2019

Login to get access

Abstract

Purpose of Review

Obesity is increasing at an alarming rate and now poses a global threat to humankind. In recent years, we have seen the emergence of medical devices to combat the obesity epidemic. These therapeutic strategies are discussed in this review dividing them into gastric and duodenal therapies.

Recent Findings

Traditionally, medical devices for obesity such as the intragastric balloon have focused on reducing gastric size, but more recently there has been a shift towards developing devices that modulate neural and hormonal responses to induce early satiety thus reducing oral intake.

Summary

Medical devices for obesity treatment may have a role in those patients who are struggling to control their weight despite significant lifestyle modifications such as diet and exercise and who decline or are unfit for bariatric surgery. For the wider adoption and integration of these devices in the obesity treatment paradigm, more long-term efficacy and safety data from randomised controlled trials are required.
Literature
1.
go back to reference WHO, Obesity and overweight. 2015. Factsheet No.31. WHO, Obesity and overweight. 2015. Factsheet No.31.
2.
go back to reference Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233–44.PubMedPubMedCentral Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233–44.PubMedPubMedCentral
3.
go back to reference Lee CM, et al. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008;61(7):646–53.PubMed Lee CM, et al. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008;61(7):646–53.PubMed
4.
go back to reference Ogden CL, Carroll MD, Flegal KM. Prevalence of obesity in the United States Letters. JAMA. 2014;312(2):189–90.PubMed Ogden CL, Carroll MD, Flegal KM. Prevalence of obesity in the United States Letters. JAMA. 2014;312(2):189–90.PubMed
5.
go back to reference Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci. 2016;130(12):943–86.PubMed Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci. 2016;130(12):943–86.PubMed
6.
go back to reference Tobias DK, Chen M, Manson JAE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(12):968–79.PubMedPubMedCentral Tobias DK, Chen M, Manson JAE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(12):968–79.PubMedPubMedCentral
7.
go back to reference Torgerson J, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.PubMed Torgerson J, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.PubMed
8.
go back to reference Hemmingsson E, Johansson K, Eriksson J, Sundström J, Neovius M, Marcus C. Weight loss and dropout during a commercial weight-loss program including a very-low-calorie diet, a low-calorie diet, or restricted normal food: observational cohort study. Am J Clin Nutr. 2012;96(5):953–61.PubMedPubMedCentral Hemmingsson E, Johansson K, Eriksson J, Sundström J, Neovius M, Marcus C. Weight loss and dropout during a commercial weight-loss program including a very-low-calorie diet, a low-calorie diet, or restricted normal food: observational cohort study. Am J Clin Nutr. 2012;96(5):953–61.PubMedPubMedCentral
9.
go back to reference Sahebkar A, Simental-Mendía LE, Reiner Ž, Kovanen PT, Simental-Mendía M, Bianconi V, et al. Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res. 2017;122:53–65.PubMed Sahebkar A, Simental-Mendía LE, Reiner Ž, Kovanen PT, Simental-Mendía M, Bianconi V, et al. Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res. 2017;122:53–65.PubMed
10.
go back to reference Busetto L, et al., Bariatric surgery in class I obesity 2014; 24(4): p. 487–519. Busetto L, et al., Bariatric surgery in class I obesity 2014; 24(4): p. 487–519.
11.
go back to reference • Colquitt JL, et al., Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014; (8): p. CD003641. Twenty -two trials with 1798 Participants were included in this systematic review. All seven RCTs that included comparing surgery with non surgical interventions found benefits of surgery on measures of weight change at 1 to 2-year follow-up. • Colquitt JL, et al., Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014; (8): p. CD003641. Twenty -two trials with 1798 Participants were included in this systematic review. All seven RCTs that included comparing surgery with non surgical interventions found benefits of surgery on measures of weight change at 1 to 2-year follow-up.
12.
go back to reference Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–7.PubMed Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–7.PubMed
13.
go back to reference Thompson CC, Abu Dayyeh BK, Kushner R, Sullivan S, Schorr AB, Amaro A, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017;112(3):447–57.PubMed Thompson CC, Abu Dayyeh BK, Kushner R, Sullivan S, Schorr AB, Amaro A, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017;112(3):447–57.PubMed
14.
go back to reference Alqahtani A, al-Darwish A, Mahmoud AE, Alqahtani YA, Elahmedi M. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc. 2019;89(6):1132–8.PubMed Alqahtani A, al-Darwish A, Mahmoud AE, Alqahtani YA, Elahmedi M. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc. 2019;89(6):1132–8.PubMed
15.
go back to reference Weiss, C.R., et al., Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) trial: results at 1 year. Radiology, 2019: p. 182354. Weiss, C.R., et al., Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) trial: results at 1 year. Radiology, 2019: p. 182354.
16.
go back to reference Sarr MG, Billington CJ, Brancatisano R, Brancatisano A, Toouli J, Kow L, et al. The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity. Obes Surg. 2012;22(11):1771–82.PubMed Sarr MG, Billington CJ, Brancatisano R, Brancatisano A, Toouli J, Kow L, et al. The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity. Obes Surg. 2012;22(11):1771–82.PubMed
17.
go back to reference Ikramuddin S, Blackstone RP, Brancatisano A, Toouli J, Shah SN, Wolfe BM, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. Jama. 2014;312(9):915–22.PubMed Ikramuddin S, Blackstone RP, Brancatisano A, Toouli J, Shah SN, Wolfe BM, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. Jama. 2014;312(9):915–22.PubMed
18.
go back to reference Rohde U, Hedbäck N, Gluud LL, Vilsbøll T, Knop FK. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(3):300–5.PubMed Rohde U, Hedbäck N, Gluud LL, Vilsbøll T, Knop FK. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(3):300–5.PubMed
19.
go back to reference Machytka E, Bužga M, Zonca P, Lautz DB, Ryou M, Simonson DC, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc. 2017;86(5):904–12.PubMed Machytka E, Bužga M, Zonca P, Lautz DB, Ryou M, Simonson DC, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc. 2017;86(5):904–12.PubMed
20.
go back to reference Gleysteen JJ. A history of intragastric balloons. Surg Obes Relat Dis. 2016;12(2):430–5.PubMed Gleysteen JJ. A history of intragastric balloons. Surg Obes Relat Dis. 2016;12(2):430–5.PubMed
21.
go back to reference Giardiello C, Borrelli A, Silvestri E, Antognozzi V, Iodice G, Lorenzo M. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg. 2012;22(12):1916–9.PubMed Giardiello C, Borrelli A, Silvestri E, Antognozzi V, Iodice G, Lorenzo M. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg. 2012;22(12):1916–9.PubMed
22.
go back to reference • Imaz I, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6 This systematic review of 15 studies found that intragastric balloons are short term effective treatments to lose weight and are well tolerated.PubMed • Imaz I, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6 This systematic review of 15 studies found that intragastric balloons are short term effective treatments to lose weight and are well tolerated.PubMed
23.
go back to reference Martins Fernandes FA Jr, et al. Intragastric Balloon for Overweight Patients Jsls, 2016; 20(1).PubMed Martins Fernandes FA Jr, et al. Intragastric Balloon for Overweight Patients Jsls, 2016; 20(1).PubMed
24.
go back to reference Moura D, Oliveira J, de Moura EGH, Bernardo W, Galvão Neto M, Campos J, et al. Effectiveness of intragastric balloon for obesity: a systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis. 2016;12(2):420–9.PubMed Moura D, Oliveira J, de Moura EGH, Bernardo W, Galvão Neto M, Campos J, et al. Effectiveness of intragastric balloon for obesity: a systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis. 2016;12(2):420–9.PubMed
25.
go back to reference Sullivan S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology. 2013;145(6):1245–52.e1–5.PubMedPubMedCentral Sullivan S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology. 2013;145(6):1245–52.e1–5.PubMedPubMedCentral
26.
go back to reference Nystrom M, et al. Aspiration therapy as a tool to treat obesity: 1- to 4-year results in a 201-patient multi-center post-market European registry study. Obes Surg. 2018;28(7):1860–8.PubMedPubMedCentral Nystrom M, et al. Aspiration therapy as a tool to treat obesity: 1- to 4-year results in a 201-patient multi-center post-market European registry study. Obes Surg. 2018;28(7):1860–8.PubMedPubMedCentral
27.
go back to reference Sharaiha RZ, Kedia P, Kumta N, DeFilippis E, Gaidhane M, Shukla A, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy. 2015;47(2):164–6.PubMed Sharaiha RZ, Kedia P, Kumta N, DeFilippis E, Gaidhane M, Shukla A, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy. 2015;47(2):164–6.PubMed
28.
go back to reference Zorron R, Veltzke-Schlieker W, Adler A, Denecke C, Dziodzio T, Pratschke J, et al. Endoscopic sleeve gastroplasty using Apollo Overstitch as a bridging procedure for superobese and high risk patients. Endoscopy. 2018;50(1):81–3.PubMed Zorron R, Veltzke-Schlieker W, Adler A, Denecke C, Dziodzio T, Pratschke J, et al. Endoscopic sleeve gastroplasty using Apollo Overstitch as a bridging procedure for superobese and high risk patients. Endoscopy. 2018;50(1):81–3.PubMed
29.
go back to reference Fayad L, Adam A, Schweitzer M, Cheskin LJ, Ajayi T, Dunlap M, et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc. 2019;89(4):782–8.PubMed Fayad L, Adam A, Schweitzer M, Cheskin LJ, Ajayi T, Dunlap M, et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc. 2019;89(4):782–8.PubMed
30.
go back to reference Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141(11):4255–61.PubMed Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141(11):4255–61.PubMed
31.
go back to reference Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623–30. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623–30.
32.
go back to reference Arepally A, Barnett BP, Patel TT, Howland V, Boston RC, Kraitchman DL, et al. Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology. 2008;249(1):127–33.PubMedPubMedCentral Arepally A, Barnett BP, Patel TT, Howland V, Boston RC, Kraitchman DL, et al. Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology. 2008;249(1):127–33.PubMedPubMedCentral
33.
go back to reference Gunn AJ, Oklu R. A preliminary observation of weight loss following left gastric artery embolization in humans. J Obes. 2014;2014:185349.PubMedPubMedCentral Gunn AJ, Oklu R. A preliminary observation of weight loss following left gastric artery embolization in humans. J Obes. 2014;2014:185349.PubMedPubMedCentral
34.
go back to reference Kordzadeh A, Lorenzi B, Hanif MA, Charalabopoulos A. Left gastric artery embolisation for the treatment of obesity: a systematic review. Obes Surg. 2018;28(6):1797–802.PubMed Kordzadeh A, Lorenzi B, Hanif MA, Charalabopoulos A. Left gastric artery embolisation for the treatment of obesity: a systematic review. Obes Surg. 2018;28(6):1797–802.PubMed
35.
go back to reference Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res. 2018;11:203–13.PubMedPubMedCentral Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res. 2018;11:203–13.PubMedPubMedCentral
36.
go back to reference de Lartigue G. Role of the vagus nerve in the development and treatment of diet-induced obesity. J Physiol. 2016;594(20):5791–815.PubMedPubMedCentral de Lartigue G. Role of the vagus nerve in the development and treatment of diet-induced obesity. J Physiol. 2016;594(20):5791–815.PubMedPubMedCentral
37.
go back to reference Camilleri M, Toouli J, Herrera MF, Kulseng B, Kow L, Pantoja JP, et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. Surgery. 2008;143(6):723–31.PubMed Camilleri M, Toouli J, Herrera MF, Kulseng B, Kow L, Pantoja JP, et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. Surgery. 2008;143(6):723–31.PubMed
38.
go back to reference Camilleri M, Toouli J, Herrera MF, Kow L, Pantoja JP, Billington CJ, et al. Selection of electrical algorithms to treat obesity with intermittent vagal block using an implantable medical device. Surg Obes Relat Dis. 2009;5(2):224–9 discussion 229-30.PubMed Camilleri M, Toouli J, Herrera MF, Kow L, Pantoja JP, Billington CJ, et al. Selection of electrical algorithms to treat obesity with intermittent vagal block using an implantable medical device. Surg Obes Relat Dis. 2009;5(2):224–9 discussion 229-30.PubMed
39.
go back to reference Shikora SA, et al. Sustained weight loss with vagal nerve blockade but not with sham: 18-month results of the ReCharge trial. J Obes. 2015;2015:365604.PubMedPubMedCentral Shikora SA, et al. Sustained weight loss with vagal nerve blockade but not with sham: 18-month results of the ReCharge trial. J Obes. 2015;2015:365604.PubMedPubMedCentral
40.
go back to reference Apovian CM, Shah SN, Wolfe BM, Ikramuddin S, Miller CJ, Tweden KS, et al. Two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge trial. Obes Surg. 2017;27(1):169–76.PubMed Apovian CM, Shah SN, Wolfe BM, Ikramuddin S, Miller CJ, Tweden KS, et al. Two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge trial. Obes Surg. 2017;27(1):169–76.PubMed
41.
go back to reference Ruban A, Ashrafian H, Teare JP. The EndoBarrier: duodenal-jejunal bypass liner for diabetes and weight loss. Gastroenterol Res Pract. 2018;2018:9. Ruban A, Ashrafian H, Teare JP. The EndoBarrier: duodenal-jejunal bypass liner for diabetes and weight loss. Gastroenterol Res Pract. 2018;2018:9.
42.
go back to reference Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55–9.PubMed Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55–9.PubMed
43.
go back to reference Betzel B, Homan J, Aarts EO, Janssen IMC, de Boer H, Wahab PJ, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc. 2017;31(7):2881–91.PubMed Betzel B, Homan J, Aarts EO, Janssen IMC, de Boer H, Wahab PJ, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc. 2017;31(7):2881–91.PubMed
44.
go back to reference Kiela PR, Ghishan FK. Physiology of intestinal absorption and secretion. Best Pract Res Clin Gastroenterol. 2016;30(2):145–59.PubMedPubMedCentral Kiela PR, Ghishan FK. Physiology of intestinal absorption and secretion. Best Pract Res Clin Gastroenterol. 2016;30(2):145–59.PubMedPubMedCentral
45.
go back to reference Diana M, Wall J, Perretta S, Dallemagne B, Gonzales KD, Harrison MR, et al. Totally endoscopic magnetic enteral bypass by external guided rendez-vous technique. Surg Innov. 2011;18(4):317–20.PubMed Diana M, Wall J, Perretta S, Dallemagne B, Gonzales KD, Harrison MR, et al. Totally endoscopic magnetic enteral bypass by external guided rendez-vous technique. Surg Innov. 2011;18(4):317–20.PubMed
46.
go back to reference Ryou M, Aihara H, Thompson CC. Minimally invasive entero-enteral dual-path bypass using self-assembling magnets. Surg Endosc. 2016;30(10):4533–8.PubMed Ryou M, Aihara H, Thompson CC. Minimally invasive entero-enteral dual-path bypass using self-assembling magnets. Surg Endosc. 2016;30(10):4533–8.PubMed
Metadata
Title
Medical Devices in Obesity Treatment
Authors
Aruchuna Ruban
Akash Doshi
Erika Lam
Julian P. Teare
Publication date
01-10-2019
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 10/2019
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-019-1217-3

Other articles of this Issue 10/2019

Current Diabetes Reports 10/2019 Go to the issue

Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)

Inpatient Diabetes Education in the Real World: an Overview of Guidelines and Delivery Models

Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D

Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)

Care of Children and Adolescents with Diabetes Mellitus and Hyperglycemia in the Inpatient Setting

Immunology, Transplantation, and Regenerative Medicine (L Piemonti and V Sordi, Section Editors)

Targeting Stem Cell-Derived Tissue-Associated Regulatory T Cells for Type 1 Diabetes Immunotherapy

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.